Quantum-Si (NASDAQ:QSI) Director Paula Dowdy Acquires 109,890 Shares of Stock

Quantum-Si Incorporated (NASDAQ:QSI) Director Paula Dowdy bought 109,890 shares of Quantum-Si stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the purchase, the director owned 269,107 shares of the company’s stock, valued at approximately $255,651.65. This trade represents a 69.02% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Quantum-Si Trading Up 7.4%

Shares of QSI opened at $0.93 on Tuesday. The firm has a market capitalization of $199.52 million, a P/E ratio of -1.78 and a beta of 3.00. Quantum-Si Incorporated has a 12-month low of $0.84 and a 12-month high of $3.10. The firm has a fifty day moving average price of $1.09 and a 200-day moving average price of $1.37.

Quantum-Si (NASDAQ:QSI) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Quantum-Si had a negative net margin of 4,160.06% and a negative return on equity of 43.90%. The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.76 million. Analysts predict that Quantum-Si Incorporated will post -0.65 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a research report on Monday, December 29th. Canaccord Genuity Group lowered their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Management Associates Inc. increased its position in Quantum-Si by 14.8% during the 3rd quarter. Wealth Management Associates Inc. now owns 30,950 shares of the company’s stock valued at $44,000 after purchasing an additional 4,000 shares during the period. SBI Securities Co. Ltd. boosted its stake in shares of Quantum-Si by 28.6% during the third quarter. SBI Securities Co. Ltd. now owns 33,616 shares of the company’s stock valued at $47,000 after purchasing an additional 7,475 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock valued at $131,000 after purchasing an additional 9,005 shares in the last quarter. SG Americas Securities LLC increased its holdings in Quantum-Si by 30.8% during the third quarter. SG Americas Securities LLC now owns 42,107 shares of the company’s stock valued at $59,000 after buying an additional 9,926 shares during the period. Finally, Capital Investment Advisory Services LLC raised its stake in Quantum-Si by 100.0% in the third quarter. Capital Investment Advisory Services LLC now owns 20,000 shares of the company’s stock worth $28,000 after buying an additional 10,000 shares in the last quarter. 39.90% of the stock is currently owned by institutional investors.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.